Specialty Pharmacy

Test may help clinicians identify the best course of therapy for patients with Diffuse Large B-Cell Lymphoma.

Immune mechanisms found to have significant impact on overcoming HCV.

Researchers seek to increase transparency and diminish the added burdens on the workforce.

Pan-virals show potential to work across all HCV genotypes.

DNA4Life has launched a new test for patients who want to know how their bodies will respond to some of the most commonly prescribed therapeutic medications.

Multiple myeloma disease development affected by pituitary tumor transforming gene.

Cheryl Allen, RPh, BSPharm, MBA, vice president of Industry Relations at Diplomat, discusses how relationships can be improved between manufacturers, pharmacy benefit managers, and pharmacies.

Research may improve the diagnosis of infectious and autoimmune diseases, including rheumatoid arthritis and HIV.

Research may minimize operations for benign disease while maintaining a low morbidity and mortality for surgical resection.

Treatment doubles overall survival of patients with recurrent glioblastoma.

Injection drug use most frequently linked to a positive hepatitis C screening.

Process makes tumors more sensitive to chemotherapy to improve targeted therapy.

Top news of the week in cancer drug development.

Exercise following diagnosis may offer significant protection among cancer survivors.

Process can improve medical care with better results for patients.

Research may offer powerful new tool in the treatment of HIV.

Top stories of the week on Specialty Pharmacy Times.

Certain pesticide contaminants found to increase risk of multiple myeloma.

Chronic hepatitis C infection linked to the prevalence of plaque and noncalcified plaque in the arteries.

App could improve cancer diagnostics in low- to middle-income and remote areas.

Study determines which genetic mutations in cancer will be most likely to respond to chemotherapy.

Rural and cancer hospitals will no longer have access to 340B discount pricing for orphan drug purchases.

The FDA today has granted accelerated approval to Boehringer Ingelheim's intravenous solution idarucizumab (Praxbind) for the rapid reversal of Pradaxa.

Synjardy, a type 2 diabetes treatment, is now available by prescription in US pharmacies.

High-dose chemotherapy and autologous stem cell transplantation show promise for patients with light-chain amyloidosis.

Processing speed linked to both activity and participation among patients with MS.

Many colon cancer disparities found in patients of different races under 50-years old.

Secukinumab shows promise in the treatment of patients with psoriatic arthritis.